Trial Profile
A Phase II Study of the Orally Administered Negative Enantiomer of Gossypol (AT-101) in Patients With Advanced Adrenocortical Carcinoma (ACC).
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs AT 101 (Primary)
- Indications Adrenocortical carcinoma
- Focus Therapeutic Use
- 14 Jun 2019 Status changed to discontinued as per results published in Investigational New Drugs
- 06 Jun 2019 Results published in the Investigational New Drugs
- 07 Feb 2013 New source identified and integrated (Mayo Clinic; 08-001344).